Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease (scientific article)

cites work (P2860)

Q41501265	"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study
Q41316306	"Isolated" low high-density lipoprotein cholesterol
Q37435149	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations
Q38071039	2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American
Q28301815	2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Q48123127	2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document
Q44645516	A Comparison of the Effects of Nevirapine and Nelfinavir on Metabolism and Body Habitus in Antiretroviral-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Controlled Study
Q91362103	A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury
Q37672465	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids
Q41495179	A brief review paper of the efficacy and safety of atorvastatin in early clinical trials
Q37268111	A cerebrovascular perspective of atherosclerosis
Q38106667	A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative.
Q37740049	A comparative review of the adverse effects of treatments for hyperlipidaemia
Q34495746	A comparison of clinical outcome studies among cholesterol-lowering agents
Q68047602	A comparison of results of a national cholesterol and blood pressure screening with the NHANES II Study: implications for further emphasis on reducing cardiovascular risk among Americans
Q36053274	A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Q27691368	A controversial step forward: A commentary on the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults
Q37179792	A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies
Q47849930	A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia
Q43734342	A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia
Q52381195	A new method of estimating cost effectiveness of cholesterol reduction therapy for prevention of heart disease.
Q53358074	A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
Q37285403	A predictor of atheroma progression in patients achieving very low levels of low-density lipoprotein cholesterol
Q38113494	A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs
Q33569334	A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants
Q38632021	A review of combined hyperlipidaemia and its treatment with fenofibrate
Q33763024	A review of recent dietary intervention trials in the United Kingdom to reduce blood cholesterol levels
Q73120700	A study to determine the response of coronary atherosclerosis to raising low high density lipoprotein cholesterol with a fibric-acid derivative in men after coronary bypass surgery. The rationale, design, and baseline characteristics of the LOCAT St
Q77124472	A tale of two trials: The West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study
Q33616750	A woman's heart. An update of coronary artery disease risk in women
Q77853784	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stab
Q40104818	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy
Q68365130	Abnormalities in plasmas concentrations of lipoproteins and fibrinogen in Type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion
Q35777411	Achieving lipid goals in Europe: how large is the treatment gap?
Q92532068	Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model
Q54050945	Activation of PPARdelta alters lipid metabolism in db/db mice.
Q95818928	Activity profile of gemfibrozil on the major plasma lipoprotein parameters
Q35918848	Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story
Q50541812	Advances in Cardiovascular Pharmacology: Protocol Design and Methodology. Proceedings of the 11th annual symposium. Atherosclerosis and Drug Development for Ischemic Heart Disease
Q37104870	Advances in the management of hyperlipidemia-induced atherosclerosis
Q41210727	Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors
Q41604710	Aggressive cholesterol management: role of the lipid nurse specialist
Q35183108	Aggressive lipid management for cardiovascular prevention: evidence from clinical trials
Q38597940	Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
Q31101617	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.
Q34081331	American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary
Q44480109	An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study
Q38877106	An increasing problem in publication ethics: Publication bias and editors' role in avoiding it.
Q40482679	An update on coronary risk factors.
Q35797202	Analysis of familial hypoalphalipoproteinemia syndromes
Q34122371	Analysis of serious adverse events. Lipid-lowering therapy revisited
Q34727160	Antiatherosclerosis interventions in women
Q33709262	Antiatherosclerotic activity of drugs in relation to nitric oxide function
Q44551868	Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk
Q85016638	Antihyperlipidemic properties of novel N-(benzoylphenyl)-5-substituted-1H-indole-2-carboxamides in Triton WR-1339-induced hyperlipidemic rats
Q36513911	Antihypertensive therapy: Taking lipids into consideration
Q39200522	Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.
Q28829054	Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism
Q46742490	Apolipoprotein a polymorphism predicts lipoprotein a concentration in renal transplant recipients.
Q64125325	Application research on PPARα-transgenic mice in preclinical safety evaluation of gemfibrozil
Q37786739	Approaches to lipid and lipoprotein analysis
Q36098067	Approaches to the management of hypercholesterolaemia
Q34575937	Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials
Q37453168	Assessing population-based programs to reduce blood cholesterol level and saturated fats
Q54434628	Assessing the benefits of lipid-lowering therapy.
Q33731842	Assessment for subclinical ischemia: bridging the gap between primary and secondary prevention
Q43667538	Assessment of hypercholesterolemia control in a managed care organization
Q73980542	Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations
Q90145015	Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
Q46409115	Association between depressive symptoms and use of HMG-CoA reductase inhibitors (statins), corticosteroids and histamine H(2) receptor antagonists in community-dwelling older persons: cross-sectional analysis of a population-based cohort.
Q92022864	Association between hyperlipidemia and mortality after incident acute myocardial infarction or acute decompensated heart failure: a propensity score matched cohort study and a meta-analysis
Q38383033	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
Q50959234	Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women.
Q64120153	Atherogenesis in Psoriasis: Evaluation of the Serum Activities of Non-high-density Lipoprotein Cholesterol and Other Lipids Among Newly Diagnosed Psoriasis Patients
Q28200554	Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
Q28538861	Atheroprotective effect of oleoylethanolamide (OEA) targeting oxidized LDL
Q37049636	Atherosclerosis and cardiovascular risk reduction with PPAR agonists
Q35651476	Atherosclerosis and physical activity
Q71774924	Atherosclerosis and restenosis: reflections on the Lovastatin Restenosis Trial and Scandinavian Simvastatin Survival Study
Q37948352	Atherosclerosis during adolescence
Q37832648	Atherosclerosis in 2010: new therapeutic insights
Q34730108	Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Q43138948	Atherosclerosis: past, present, and future.
Q33762050	Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies
Q41019483	Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
Q41454232	Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias
Q47801721	Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong
Q34103824	Attitudes and practices of primary care physicians in the management of elevated serum cholesterol levels.
Q41545644	Automated serial ECG comparison based on the Minnesota code
Q41386366	Barriers to lifestyle change, and the need to develop an integrated approach to prevention
Q35585971	Barriers to preventive interventions for coronary heart disease
Q35809770	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
Q34276278	Basic data related to lipid abnormalities in peripheral vascular disease
Q47702888	Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study
Q35549437	Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study
Q33670420	Best practice--ongoing polemics
Q34107570	Beyond cholesterol lowering: deciphering the benefits of dietary intervention on cardiovascular diseases
Q38100747	Beyond statins: lipid management to reduce cardiovascular risk
Q35271636	Beyond the mega-trial: certainty and uncertainty
Q70177759	Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells
Q34270340	Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
Q41445502	Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia
Q69367434	Blood cholesterol: is population screening warranted in the UK?
Q36723502	Borderline hypercholesterolaemia: when to introduce drugs
Q44656380	Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries
Q40854503	Broadening the evidence base for evidence-based guidelines. A research agenda based on the work of the U.S. Preventive Services Task Force
Q36884264	By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
Q42192532	CI-924 effects on plasma lipids in patients with type II and type IV hyperlipoproteinaemia
Q74143838	Can single photon emission computed tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia?
Q56986316	Can we dramatically reduce the incidence of coronary heart disease?
Q21261519	Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis
Q33559991	Cardiac rehabilitation. Current status and future directions
Q38176275	Cardiometabolic impact of non-statin lipid lowering therapies
Q37161933	Cardiometabolic interventions - focus on transcriptional regulators
Q36678894	Cardioprotective therapeutics--drugs used in hypertension, hyperlipidaemia, thromboembolism, arrhythmias, the postmenopausal state and as anti-oxidants
Q35151325	Cardiovascular complications of diabetes: prevention and management
Q44651073	Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care
Q38845392	Cardiovascular disease risk in people with spinal cord injury: is there a possible association between reduced lung function and increased risk of diabetes and hypertension?
Q36419283	Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities
Q37762838	Cardiovascular disease, SCI and exercise: unique risks and focused countermeasures
Q34241802	Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data
Q40100018	Cardiovascular risk and dyslipidemia among persons living with HIV: a review
Q34038507	Cardiovascular risk changes after lipid lowering medications: are they predictable?
Q45162751	Cardiovascular risk of SCORE compared to Framingham. Consequences of the change proposed by the European Societies
Q36657476	Cardiovascular therapies in the 1990s. An overview
Q34592173	Cerivastatin-induced rhabdomyolysis: 11 case reports
Q51301866	Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?
Q37173568	Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy
Q36890445	Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland
Q39442935	Changes over time in blood lipids and their correlates in Polish rural and urban populations: the Poland-United States Collaborative Study in cardiopulmonary disease epidemiology
Q41086603	Changing physicians' attitudes, knowledge, and self-efficacy regarding cholesterol screening and management.
Q35188360	Choices for treatment of hyperlipidaemia
Q35168203	Cholesterol absorption inhibitors: defining new options in lipid management.
Q35359085	Cholesterol and coronary disease--outstanding questions
Q38640321	Cholesterol and diet
Q35633523	Cholesterol and lipoproteins: beyond atherogenesis
Q38138095	Cholesterol can be lowered in older persons. Should we care?
Q72248265	Cholesterol confusion in primary prevention of coronary artery disease
Q33777699	Cholesterol lowering and endothelial function
Q28270339	Cholesterol lowering and mortality: the importance of considering initial level of risk
Q36102962	Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets
Q29029379	Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome
Q33613233	Cholesterol reduction in the prevention of coronary heart disease: therapeutic rationale and guidelines. The British Hyperlipidaemia Association
Q36520594	Cholesterol screening: introducing new technology from the ontario task force on the use and provision of medical services
Q69241762	Cholesterol testing
Q37030666	Cholesterol trials and mortality
Q33286262	Cholesterol--when is lower better?
Q41063543	Cholesterol-lowering therapy: is there really a controversy?
Q72726075	Cholesterol-lowering therapy: what patients expect in return
Q64237421	Cholesterol: Can't Live With It, Can't Live Without It
Q45224087	Cholesterolemia control in Spain, 2000: a tool for cardiovascular disease prevention
Q38832478	Cholesteryl Ester Transfer Protein Inhibitors: Trials and Tribulations
Q33590777	Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors
Q39446259	Choosing the most appropriate treatment for stable angina. Safety considerations
Q41445464	Choosing the right lipid-regulating agent. A guide to selection
Q30833531	Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data
Q43956075	Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study
Q47242967	Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men.
Q64075657	Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
Q89585086	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy
Q72592903	Clinical and angiographic variables affecting the progression of coronary artery disease as determined by quantitative angiography
Q36952970	Clinical considerations regarding treatment of hypercholesterolemia in the elderly
Q34461377	Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus
Q68085081	Clinical experience with simvastatin compared with cholestyramine
Q35695439	Clinical interest of PPARs ligands
Q73108685	Clinical outcome in venous coronary artery bypass grafting: a 15-year follow-up study
Q43263960	Clinical pharmacology and therapeutics
Q33646070	Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols
Q38025700	Clinical relevance of hyperlipidemia
Q40394318	Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment
Q35722920	Clinical trials and lipid guidelines for type II diabetes
Q35070830	Clinician's guide to the updated ABCs of cardiovascular disease prevention
Q44129087	Clofibrate improves glucose tolerance in fat-fed rats but decreases hepatic glucose consumption capacity.
Q28728567	Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy
Q40440943	Clustering of cardiovascular risk factors: Targeting high-risk individuals
Q34027325	Combination drug therapy for combined hyperlipidemia
Q34107165	Combination drug therapy for dyslipidemia.
Q82496374	Combination lipid therapy in type 2 diabetes
Q36812752	Combination therapy in cholesterol reduction: focus on ezetimibe and statins.
Q30434678	Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome.
Q37855939	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus
Q33731864	Combined hyperlipidemia as a risk factor for premature atherosclerotic disease
Q50712735	Combined organ failure with combination antihyperlipidemic treatment: a case of hepatic injury and acute renal failure.
Q24195172	Combined therapy with statins and fibrates for people with dyslipidaemia
Q24243737	Combined therapy with statins and fibrates for people with dyslipidaemia
Q37875049	Common sense treatment for common lipid disorders.
Q36707882	Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?
Q53832429	Comparative Evaluation of Gemcabene and PPAR Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
Q33956562	Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care
Q40921761	Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
Q34045770	Comparative tolerability of the HMG-CoA reductase inhibitors
Q72797350	Comparison of iodine-123 low-density lipoprotein (LDL) and indium-111 LDL binding to mononuclear cells of healthy normolipaemic controls and patients with heterozygous familial hypercholesterolaemia
Q69547243	Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group
Q34579830	Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus
Q70975000	Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia
Q72676670	Completeness of reporting trial results: effect on physicians' willingness to prescribe
Q33562106	Compliance in clinical trials
Q42605793	Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study Team
Q68065234	Compliance with medication in the Helsinki Heart Study
Q35729368	Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators
Q39409421	Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus
Q74798330	Control of lipid disorders in patients with atherosclerotic vascular disease
Q43122651	Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?
Q42547129	Conveying the benefits and risks of treatment.
Q71955932	Coronary Artery Disease in Heterozygous Familial Hypercholesterolemia Patients With the Same LDL Receptor Gene Mutation
Q54180620	Coronary artery bypass grafting in familial hypercholesterolemia.
Q34052597	Coronary artery disease and human immunodeficiency virus infection
Q39470275	Coronary heart disease is not preventable by population interventions
Q44611700	Correlation between bone mineral density and plasma lipids in Taiwan
Q43641335	Correlation between serum lipid concentrations and psychological distress
Q44852235	Correlations between lipid levels and age, gender, glycemia, obesity, diabetes, and smoking
Q69240392	Cost effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin versus cholestyramine
Q35179315	Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while?
Q45301826	Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease
Q41157722	Cost-effective treatment of coronary artery disease--the new imperative
Q43266394	Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD.
Q50973812	Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain.
Q74823031	Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson)
Q37808517	Costs and benefits of risk factor reduction for coronary heart disease: insights from screening and treatment of serum cholesterol
Q40424562	Cost‐effectiveness of alternative interventions for the prevention and treatment of coronary heart disease
Q36058567	Critical appraisal of revised cholesterol guidelines for the very high-risk patient
Q38546242	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
Q41171297	Current concepts in the management of hypercholesterolemia with an update on fluvastatin. Introduction
Q37702199	Current guidelines for high-density lipoprotein cholesterol in therapy and future directions.
Q38365112	Current management of acute myocardial infarction
Q33715404	Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.
Q43812794	Current ways of treating dyslipidemias to prevent atherosclerosis.
Q33993678	Current, new and future treatments in dyslipidaemia and atherosclerosis
Q33485663	Currently available hypolipidaemic drugs and future therapeutic developments
Q39603874	Currently available lipid-lowering agents
Q71032690	Cytochrome P450 and atherosclerosis
Q34545343	Cytochrome P450 and xenobiotic receptor humanized mice
Q36911423	Cytochrome P450--physiological key factor against cholesterol accumulation and the atherosclerotic vascular process
Q46460104	Cytoprotective gene HO-1 and chronic rejection in heart transplantation.
Q24793512	Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl"
Q41220381	Delayed progression or regression of coronary atherosclerosis with intensive risk factor modification. Effects of diet, drugs, and exercise
Q38141575	Demystifying the management of hypertriglyceridaemia.
Q73606176	Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Q24805756	Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421
Q56483522	Design of the Women’s Health Initiative Clinical Trial and Observational Study
Q57274411	Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Re
Q73895987	Design, synthesis and structure-activity relationship studies of novel 4,4-bis(trifluoromethyl)imidazolines as acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents
Q43566112	Detection of the "midband" lipoprotein in patients with coronary artery spasm.
Q36916525	Detergent-mediated phospholipidation of plasma lipoproteins increases HDL cholesterophilicity and cholesterol efflux via SR-BI.
Q44236160	Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients
Q68204603	Determination of the novel hydroxymethyl glutaryl coenzyme A reductase inhibitor (RP 61969) and its dihydroxy acid hydrolysis product in human plasma by reversed-phase high-performance liquid chromatography
Q43718360	Developing a clinical strategy for cholesterol management in an era of unanswered questions
Q34742639	Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physicians
Q34530098	Diabetes & coronary heart disease: current perspectives
Q34371760	Diabetes care in general practice: an approach to audit of process and outcome
Q33652018	Diabetes, hyperlipidemia, and coronary artery disease
Q33446544	Diabetes: managing dyslipidaemia
Q31729104	Diabetes: statins, fibrates, or both?
Q37119313	Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials
Q81315582	Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials
Q37757979	Diabetic dyslipidemia: extending the target beyond LDL cholesterol
Q46114213	Did grandma give you heart disease? The new battle against coronary artery disease
Q70626190	Diet and coronary heart disease
Q90596855	Diet-Induced Circadian Enhancer Remodeling Synchronizes Opposing Hepatic Lipid Metabolic Processes
Q35645137	Dietary and pharmacologic management of cholesterol
Q37886985	Dietary fiber and coronary heart disease
Q38269005	Dietary prevention of coronary artery disease. How to help patients modify eating habits and reduce cholesterol
Q93622713	Digest
Q35825588	Discontinuation and switching of therapy after initiation of lipid-lowering drugs: the effects of comorbidities and patient characteristics
Q57418384	Distribution of serum apolipoproteins A-I and B and lipoprotein(a) in European elderly
Q35558425	Do changes in cardiovascular risk factors explain the increasing socioeconomic difference in mortality from ischaemic heart disease in Finland?
Q34368284	Do our patients receive maximum benefit from preventive care? A North American perspective
Q37972824	Do persons with diabetes benefit from combination statin and fibrate therapy?
Q43511123	Do statins cause cancer? A meta-analysis of large randomized clinical trials
Q33776187	Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?
Q44176624	Does increased leukotriene B4 in type 1 diabetes result from elevated cholesteryl ester transfer protein activity?
Q54187934	Does lowering of cholesterol levels influence functional properties of large arteries?
Q37119252	Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Q93687085	Dr. Horlick responds
Q36712986	Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors
Q74692842	Drug administration in patients with diabetes mellitus. Safety considerations
Q37742381	Drug intervention trials in dyslipidemia: the past and the future
Q35990172	Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priority
Q28319013	Drug-induced gallbladder disease. Incidence, aetiology and management
Q40017196	Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Q53099325	Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.
Q34168379	Dyslipidaemia and cardiovascular risk in diabetes
Q35029623	Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment
Q38508952	Dyslipidemia and cardiovascular disease in women
Q37311034	Dyslipidemia and cardiovascular risk: the importance of early prevention
Q71988511	Dyslipidemia and coronary artery disease
Q26851294	Dyslipidemia and its therapeutic challenges in renal transplantation
Q36124897	Dyslipidemia and lipid-lowering therapy in the elderly
Q45155924	Dyslipidemia in patients with angiographically confirmed coronary artery disease--an opportunity for improvement
Q37447007	Dyslipidemia in patients with chronic and end-stage kidney disease
Q46116452	Dyslipidemia in type 2 diabetes mellitus
Q38088216	Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management
Q37582481	Dyslipidemia in women: etiology and management
Q41431068	Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus
Q50068800	Dyslipidemias in diabetic patients.
Q44169120	Dyslipoproteinemia and coronary disease
Q37934887	Dyslipoproteinemia and diabetes.
Q34578720	Early detection and treatment of hyperlipidemia: physician practices in Canada
Q48913750	Early determination of serum lipids and apolipoproteins in acute myocardial infarction: possibility for immediate intervention.
Q38325814	Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
Q30573704	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs
Q30573715	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective
Q35556962	Effect of 14 weeks of resistance training on lipid profile and body fat percentage in premenopausal women
Q67896761	Effect of Partial Ileal Bypass Surgery on Coronary Heart Disease
Q41172823	Effect of a combination of gemfibrozil and niacin on lipid levels
Q37364953	Effect of a multivitamin preparation supplemented with phytosterol on serum lipids and infarct size in rats fed with normal and high cholesterol diet
Q74287080	Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men
Q71814953	Effect of a synthetic prostaglandin E2 analogue, RS-86505-007, on plasma lipids and lipoproteins in patients with moderate hypercholesterolaemia: efficacy and tolerance of treatment and response in different apolipoprotein polymorphism groups
Q89608566	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
Q44556844	Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia
Q44937720	Effect of cholesterol-lowering diets on indices of depression and hostility.
Q36560348	Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial
Q37484551	Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome
Q44120848	Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells
Q33595038	Effect of high-carbohydrate versus high-monounsaturated fatty acid diet on metabolic control in diabetes and hyperglycemic patients
Q38089207	Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development.
Q73421771	Effect of lipoproteins on cultured human mesangial cells
Q74598136	Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl
Q73246121	Effect of serum cholesterol levels on meta-chlorophenylpiperazine-evoked neuroendocrine responses in healthy subjects
Q51603340	Effect of simvastatin on high density lipoprotein subfractions and apolipoproteins in type IIa hypercholesterolemia.
Q54440502	Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.
Q34533848	Effect of tablet splitting on serum cholesterol concentrations
Q46107128	Effect of very low LDL-cholesterol on cortisol synthesis
Q28244205	Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Q35266425	Effective treatment of hypertension in patients with diabetes mellitus
Q73980526	Effectiveness of antihyperlipidemic drug management in clinical practice
Q72386594	Effectiveness of coronary heart disease risk management in high-risk patients
Q30310112	Effectiveness of multiple antilipidemic agents on Vertical Auto Profile II guided treatment of dyslipoproteinemia
Q37672728	Effects of D-003, a mixture of high-molecular-weight sugar cane wax acids, on lipid peroxidation markers in older individuals: A randomized, double-blind, placebo-controlled study
Q70191712	Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis
Q39554998	Effects of acebutolol on the serum lipid profile
Q44397618	Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
Q44605265	Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
Q71301223	Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts
Q51569108	Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.
Q83549170	Effects of combination lipid therapy in diabetes mellitus
Q33889260	Effects of combination lipid therapy in type 2 diabetes mellitus
Q85937418	Effects of d-003, a new hypocholesterolaemic and antiplatelet compound, on lipid profile and lipid peroxidation in healthy volunteers
Q39554992	Effects of diuretic drugs on the lipid profile
Q37977342	Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part II).
Q51618459	Effects of exercise and fat ingestion on high density lipoprotein production by peripheral tissues.
Q70249674	Effects of exercise on plasma lipoprotein levels and endothelium-dependent vasodilatation in young and old rats
Q43674954	Effects of fenofibrate and gemfibrozil on plasma homocysteine
Q79778566	Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
Q33576435	Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Q28328142	Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins
Q44247521	Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy
Q44016352	Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia
Q57398917	Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients
Q84845727	Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (Pimephales promelas)
Q43201825	Effects of gemfibrozil on the oxygen transport properties of erythrocytes.
Q44789811	Effects of gemfibrozil treatment on vascular reactivity of streptozotocin-diabetic rat aorta
Q71434209	Effects of growth hormone on serum lipids and lipoproteins: possible significance of increased peripheral conversion of thyroxine to triiodothyronine
Q67769877	Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity
Q50110341	Effects of hypocholesterolemic dietary and drug therapy on measures of dysphoric emotions.
Q30080004	Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
Q68561986	Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia
Q43664066	Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia
Q28333637	Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension
Q36055271	Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
Q60924346	Effects of reducing LDL and increasing HDL with gemfibrozil in experimental coronary lesion development and thrombotic risk
Q73009142	Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels
Q44482530	Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia
Q36077149	Effects of statins on cardiorenal syndrome.
Q34189111	Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism
Q73286993	Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
Q74183812	Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia
Q29547856	Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
Q58823409	Efficacy and safety of fluvastatin, a new HMG CoA reductase inhibitor, in elderly hypercholesterolaemic women
Q38704457	Efficacy and tolerability of simvastatin (MK-733).
Q33815841	Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke
Q58179132	Efficacy of Gemfibrozil in Dyslipidaemic Subjects with Suspected Heart Disease. An Ancillary Study in the Helsinki Heart Study Frame Population
Q34601330	Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Q51090926	Electronic monitoring of compliance to lipid-lowering therapy in clinical practice.
Q44132084	Elevated high-density-lipoprotein cholesterol and normal triglycerides as markers of longevity
Q34768109	Elucidation of mechanisms of actions of thymoquinone-enriched methanolic and volatile oil extracts from Nigella sativa against cardiovascular risk parameters in experimental hyperlipidemia
Q38263909	Emerging drugs for hyperlipidaemia: an update
Q34619115	Emerging drugs for hyperlipidemia
Q38217102	Emerging therapeutic approaches to treat dyslipidemia
Q34808379	Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism
Q34981113	Endothelial lipase: a new lipase on the block
Q34830395	Endothelial lipase: direct evidence for a role in HDL metabolism
Q37812007	Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure
Q40791661	Enteroviruses and myocardial infarction
Q33935008	Epidemiologic association of Chlamydia pneumoniae and atherosclerosis: the initial serologic observation and more
Q44178748	Epidemiologic study of type 2 diabetes in Taiwan
Q33352441	Epidemiological link between low cholesterol and suicidality: a puzzle never finished
Q40667293	Epidemiology of sudden coronary death: an overview
Q41609559	Ethanol stimulates apolipoprotein A-I secretion by human hepatocytes: Implications for a mechanism for atherosclerosis protection
Q43784215	Ethnic variations in response to a statin (EVIREST).
Q24608464	Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline
Q44464581	Evaluation of apolipoprotein A-I kinetics in rabbits in vivo using in situ and exogenous radioiodination methods
Q34362558	Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study
Q71567066	Evidence-based management of dyslipidaemia
Q34880292	Evolving targets for lipid-modifying therapy
Q38058381	Examining the safety of PPAR agonists - current trends and future prospects
Q39579088	Experiences from hypertension trials. Impact of other risk factors
Q90722135	Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Q40421142	Extending the benefit of lipid-regulating therapy to primary prevention
Q44804875	Ezetimibe: a novel option for lowering cholesterol
Q77452768	Factors affecting high-density lipoproteins
Q40734204	Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients
Q36346866	Factors of compliance in patients with hypercholesterolemia using rosuvastatin in primary care
Q36703114	Facts and principles learned at the 39th Annual Williamsburg Conference on Heart Disease
Q40802354	Familial lipoprotein disorders and premature coronary artery disease.
Q72817617	Fat and cholesterol in the diet of infants and young children: implications for growth, development, and long-term health
Q35631548	Fatty acid composition of the diet: impact on serum lipids and atherosclerosis
Q44206732	Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Q42283686	Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia
Q37770249	Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Q30768601	Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation
Q37898699	Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia
Q42281309	Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases
Q33736139	Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome
Q36730543	Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial
Q43739783	Fenofibrate-Induced elevation in serum creatinine
Q35048009	Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management
Q44502945	Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.
Q28220294	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review
Q28284661	Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
Q90377775	Fibrate pharmacogenomics: expanding past the genome
Q36562239	Fibrate therapy in patients with metabolic syndrome and diabetes mellitus
Q44922813	Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients
Q94454408	Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Q36679599	Fibrates after the FIELD study: Some answers, more questions
Q42218338	Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2.
Q28287250	Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
Q43823655	Fibrates and homocysteine
Q38260501	Fibrates and niacin: is there a place for them in clinical practice?
Q30241199	Fibrates for primary prevention of cardiovascular disease events.
Q24186376	Fibrates for secondary prevention of cardiovascular disease and stroke
Q35602779	Fibrates for treatment of the metabolic syndrome
Q24195161	Fibrates for type 2 diabetes mellitus
Q24204016	Fibrates for type 2 diabetes mellitus
Q43050781	Fibrates in CVD: a step towards personalised medicine
Q49571281	Fibrates in the management of atherogenic dyslipidemia.
Q36742410	Fibrates: what have we learned in the past 40 years?
Q73477801	Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol
Q42738034	Financing health care
Q68603148	Fish oil supplementation in patients with stable claudication
Q41178007	Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia
Q39603889	Focus on fenofibrate
Q33912099	Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
Q67992087	Formulary policy for cholesterol reduction
Q37337457	Four additional mouse crosses improve the lipid QTL landscape and identify Lipg as a QTL gene
Q93502872	Frequency of citation and outcome of cholesterol lowering trials
Q40840477	Future of lipid-lowering trials: what else do we need to know?
Q68876734	Gemfibrozil absorption and elimination in kidney and liver disease
Q72030131	Gemfibrozil and Mediterranean diet for patients with high plasma levels of lipoprotein [Lp(a)] and cholesterol--pilot study
Q73936444	Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies
Q44759033	Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy
Q47890379	Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia
Q38756974	Gemfibrozil in Combination with Statins-Is It Really Contraindicated?
Q54384411	Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
Q37020264	Gemfibrozil ingestions reported to Texas poison control centers, 2000-2005.
Q44053509	Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia
Q28377488	Gemfibrozil metabolite inhibits in vitro low-density lipoprotein (LDL) oxidation and diminishes cytotoxicity induced by oxidized LDL
Q44735807	Gemfibrozil plus cholestyramine in familial hypercholesterolaemia
Q73779978	Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance
Q53915752	Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study.
Q37411250	Gemfibrozil, stretching arms beyond lipid lowering
Q43500649	Gemfibrozil-induced headache
Q37637746	Gemfibrozil-induced myositis in a patient with normal renal function
Q41060497	Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia
Q39540986	Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia
Q38337237	Gender, lipoproteins, diet, and cardiovascular risk. Sauce for the goose may not be sauce for the gander
Q41152438	Gender-based mortality follow-up from the Program on the Surgical Control of the Hyperlipidemias (POSCH) and meta-analysis of lipid intervention trials. Women in POSCH and other lipid trials
Q40561412	Global policy: aspects of diabetes in India
Q40748807	Global risk assessment for lipid therapy to prevent coronary heart disease
Q37679034	Glycosylated Haemoglobin (HbA1c) - A Marker of Circulating Lipids in Type 2 Diabetic Patients
Q36801131	Guar gum: a miracle therapy for hypercholesterolemia, hyperglycemia and obesity
Q68516033	Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias
Q67825792	Guidelines for the management of hyperlipidaemia in general practice. Towards the primary prevention of coronary heart disease. Royal College of General Practitioners
Q55257404	HDL Mimetics Infusion and Regression of Atherosclerosis: Is It Still Considered a Valid Therapeutic Option?
Q37742364	HDL and atherosclerosis: an update
Q30251918	HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation
Q36058450	HDL as a target in the treatment of atherosclerotic cardiovascular disease
Q74277711	HDL cholesterol: trends in two southeastern New England communities, 1981-1993
Q41128681	HDL heterogeneity and atherosclerosis.
Q35754375	HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease.
Q33756038	HDL superphospholipidation enhances key steps in reverse cholesterol transport
Q46866176	HDL--is it too big to fail?
Q41900752	HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study
Q61795332	HDL-cholestérol et approche thérapeutique
Q38217089	HDL: to treat or not to treat?
Q33604216	HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications
Q32050110	HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data
Q34236671	HMG-CoA reductase inhibitors
Q33956728	HMG-CoA reductase inhibitors and myotoxicity
Q40582669	Haemostatic function, arterial disease and the prevention of arterial thrombosis
Q52049684	Health benefits of aerobic exercise.
Q38139564	Health promotion and disease prevention in older people. Our current state of ignorance
Q38338930	Health promotion and the compression of morbidity
Q50947374	Healthcare decisions and product labeling: results of a consumer comprehension study of prototype labeling for proposed over-the-counter cholestyramine.
Q33821315	Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease
Q70267201	Helsinki Heart Study. New perspectives in the prevention of coronary heart disease
Q34734778	Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk
Q35184569	Hepatotoxicity of hypolipidemic drugs
Q38624772	High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need
Q37043222	High density lipoprotein and cardiovascular diseases.
Q33610332	High density lipoprotein cholesterol and triglycerides as markers of angiographically assessed coronary artery disease
Q37264429	High density lipoprotein: a therapeutic target in type 2 diabetes
Q35152178	High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions
Q34313937	High density lipoproteins-based therapies for cardiovascular disease
Q45973328	High level expression of human apolipoprotein A-I in transgenic rats raises total serum high density lipoprotein cholesterol and lowers rat apolipoprotein A-I
Q44966740	High remnant lipoprotein levels in patients with variant angina
Q33746611	High risk strategies for atherosclerosis
Q28085143	High-Density Lipoprotein Processing and Premature Cardiovascular Disease
Q38965138	High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.
Q35844499	High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome
Q34491368	High-density lipoprotein cholesterol and treatment guidelines
Q37924718	High-density lipoprotein cholesterol. Recommendations for routine testing and treatment
Q37400405	High-density lipoprotein cholesterol: current perspective for clinicians
Q44653930	High-density lipoprotein subfractions, apolipoproteins and antipyrine clearance in normal subjects
Q37707412	High-density lipoproteins and cardiovascular disease: 2010 update
Q71939710	High‐density lipoprotein cholesterol level and smoking modify the prognosis of patients with coronary vasospasm
Q35738372	How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?
Q34400638	How well tolerated are lipid-lowering drugs?
Q36972920	Hypercholesterolaemia in aged patients. To treat or not to treat?
Q34371039	Hypercholesterolaemia: setting a Dutch national standard
Q41526046	Hypercholesterolemia in the United States: how far have we come?
Q42251461	Hypercholesterolemia.
Q34102973	Hypercholesterolemia: a reversible risk factor for coronary heart disease
Q33584555	Hypercoagulable state leading to paraplegia in a middle-aged man.
Q67888592	Hyperlipidaemia and Coronary Risk the Scottish Lipid Consensus Group
Q37786753	Hyperlipidaemia and hypertension
Q37786745	Hyperlipidaemia and renal disease
Q34368264	Hyperlipidaemia in general practice: three year follow up of an opportunistic screening project
Q40585379	Hyperlipidaemia, hypertension, and coronary heart disease.
Q33986367	Hyperlipidemia
Q41274481	Hyperlipidemia versus iron overload and coronary artery disease: yet more arguments on the cholesterol debate
Q44370947	Hyperlipidemia. What to do when life-style changes aren't enough
Q58281353	Hypertension, Plasma Lipids and Antihypertensive Drugs
Q39181612	Hypertriglyceridaemia and risk of coronary artery disease
Q37786770	Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease
Q60533968	Hypertriglyceridemia
Q88697605	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Q72758268	Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate
Q40864746	Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
Q35686315	Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review
Q36301252	Hypertriglyceridemia-why, when and how should it be treated?
Q24672914	Hypertriglyceridemia: its etiology, effects and treatment
Q73887951	Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy
Q30244825	Hypertriglyceridemia: the importance of identifying patients at risk
Q85159855	Hypocholesterolaemic effect of dietary inclusion of two putative probiotic bile salt hydrolase-producing Lactobacillus plantarum strains in Sprague-Dawley rats
Q46790864	Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam in high-fat diet fed wistar rats
Q44119659	Hypolipidaemic activity of seaweed from Karachi coast
Q73273638	Hypolipidaemic effect of Myristica fragrans fruit extract in rabbits
Q44176614	Hypothesis - the J-shaped follow-up relation between mortality risk and disease risk-factor is due to statistical confounding
Q27675297	Identification and Mechanism of 10-Carbon Fatty Acid as Modulating Ligand of Peroxisome Proliferator-activated Receptors
Q42110948	Identification of noncalcified plaque in young persons with diabetes: an opportunity for early primary prevention of coronary artery disease identified with low-dose coronary computed tomographic angiography
Q34030905	Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy
Q35718098	Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study
Q33646056	Impact of dyslipidaemia. Lessons from clinical trials
Q71852137	Implications of 4S evidence on baseline lipid levels
Q34166361	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?
Q36232351	Implications of recent results of long term multifactorial primary prevention of cardiovascular diseases
Q35197106	Implications of the heart protection study for reducing coronary events in high-risk patients
Q43029247	Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?
Q44341495	Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease
Q47844045	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Q37661037	Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the pravastatin anti-atherosclerosis trial in the elderly (PATE).
Q37743416	Indications for lipid-lowering drugs
Q33935040	Infection and inflammation-induced proatherogenic changes of lipoproteins
Q34237195	Influence of age on the metabolism of plasma low density lipoproteins in healthy males
Q47889421	Influence of bilateral oophorectomy upon lipid metabolism
Q36887008	Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration
Q67769862	Influence of severity of heart failure on the efficacy of angiotensin-converting enzyme inhibition
Q44097757	Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil
Q41033009	Influences on the quality of published drug studies
Q93049588	Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia
Q43929860	Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D003, a mixture of very long-chain saturated fatty acids
Q58421229	Inhibition of tissue-factor-mediated thrombin generation by simvastatin
Q71876398	Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery
Q30597720	Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population
Q79778557	Insufficient treatment of hypercholesterolemia among patients hospitalized with chest pain
Q41718753	Insulin and coronary artery disease: is syndrome X the unifying hypothesis?
Q34698887	Insulin resistance and atherosclerosis
Q44182745	Insulin sensitivity markers: predictors of accidents and suicides in Helsinki Heart Study screenees
Q34679612	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease
Q77445283	Interim report from project ImPACT: hyperlipidemia
Q53407012	International nifedipine trial on anti-atherosclerotic therapy (INTACT)--methodologic implications and results of a coronary angiographic follow-up study using computer-assisted film analysis.
Q35036652	Is atherosclerotic vascular disease related to a high-fat diet?
Q37073546	Is raising HDL a futile strategy for atheroprotection?
Q34426049	Is the fatty meal a trigger for acute coronary syndromes
Q71608522	Is there a pathology of prevention? The implications of visualizing the invisible in screening programs
Q40953049	Is there an association among low untreated serum lipid levels, anger, and hazardous driving?
Q50188483	Is there an association between lipid-lowering drugs and cholecystectomy?
Q36459864	Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women?
Q35808362	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Q58362346	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
Q63977549	Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association
Q35876408	K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome
Q36520555	Knowledge and Attitudes of Physicians about Lipids
Q33734633	Knowledge, patterns of care, and outcomes of care for generalists and specialists
Q35747811	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Q37115922	Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey
Q57113485	Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis
Q37254289	Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content
Q38110701	Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.
Q69650145	Late carotid restenosis: aetiologic factors for recurrent carotid artery stenosis during long-term follow-up
Q37772422	Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol.
Q43752820	Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia
Q35856888	Lessons learned from the prospective pravastatin pooling project
Q36895086	Letter from Chicago: Stampede
Q43983868	Levels of serum cholesterol in a catalan population. Evolution over a 6- year period (1994-1996)
Q44031449	Lifestyle change and high-density lipoprotein change: the US Department of Veterans Affairs Normative Aging Study
Q33919718	Lipid Lowering Activity of Anthocephalus indicus Root in Hyperlipidemic Rats.
Q51737068	Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.
Q51054202	Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.
Q37660663	Lipid abnormalities in renal disease
Q35087481	Lipid abnormalities in the metabolic syndrome
Q37853015	Lipid control in patients with diabetes mellitus
Q35898718	Lipid intervention trials in primary prevention: a critical review
Q38714979	Lipid levels and risk of atherosclerotic coronary heart disease in the older person.
Q35168207	Lipid lowering drugs
Q37902579	Lipid lowering therapy in type 2 diabetes
Q41386341	Lipid lowering: the case for identifying and treating the high-risk patient
Q58561315	Lipid management in patients with chronic kidney disease
Q34530349	Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention
Q41195299	Lipid management: current diet and drug treatment options
Q33954412	Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines
Q35170445	Lipid screening: is it enough to measure total cholesterol concentration?
Q44249564	Lipid-lowering efficacy of hesperetin metabolites in high-cholesterol fed rats
Q47779378	Lipid-lowering therapy and long-term survival in heart transplantation
Q33654065	Lipid-lowering therapy for the primary prevention of coronary heart disease
Q33942357	Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?
Q33746602	Lipids and vascular disease: what we do and do not know
Q36310307	Lipids for psychiatrists - an overview.
Q55556596	Lipids in Non-insulin Dependent Diabetes: A Case for Treatment?
Q35647750	Lipids, atherosclerosis, and restenosis after percutaneous transluminal coronary angioplasty
Q38216087	Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy
Q41148759	Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants
Q30326951	Lipoprotein A-I structure.
Q40912350	Lipoprotein metabolism and renal failure
Q77452740	Lipoproteins and atherogenesis
Q30499944	Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial
Q67856224	Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolaemia
Q68146268	Long-term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption
Q77933878	Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
Q37837451	Longitudinal biobanks-based study on the joint effects of infections, nutrition and hormones on risk of prostate cancer
Q36557578	Loss of resistance to dietary cholesterol in the rat after hypophysectomy: importance of the presence of growth hormone for hepatic low density lipoprotein-receptor expression
Q70177756	Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia
Q44796323	Low cholesterol and increased risk
Q73091584	Low density lipoprotein (LDL) binding affinity for the LDL receptor in hyperlipoproteinemia
Q44297631	Low density lipoprotein particles are small in patients with coronary vasospasm
Q35650429	Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
Q35822906	Low serum cholesterol concentration and short term mortality from injuries in men and women
Q40520579	Low serum cholesterol increases the risk of noncardiovascular events: an antagonist viewpoint
Q43905985	Low-density lipoprotein apheresis: clinical results with different methods
Q42640945	Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study
Q67582094	Low-dose, time-release nicotinic acid: effects in selected patients with low concentrations of high-density lipoprotein cholesterol
Q89040695	Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?
Q35170262	Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials
Q72248268	Lowering cholesterol for prevention of coronary heart disease--problems and perspectives
Q35588973	Lowering cholesterol, 1988. Rationale, mechanisms, and means
Q67489059	Lynestrenol induced therapeutic amenorrhea: Effects of dose reduction on serum sex‐hormones and lipids
Q44775671	Major differences in cardiovascular risk indicators by educational status. Results from a population based screening program
Q38708536	Management of blood lipid abnormalities in coronary heart disease patients
Q36865071	Management of coronary artery disease in patients with type 2 diabetes mellitus
Q37368012	Management of coronary heart disease in the elderly
Q37707165	Management of dyslipidemia in people with type 2 diabetes mellitus
Q34722828	Management of dyslipidemia in women in the post-hormone therapy era.
Q35692886	Management of dyslipidemias in the age of statins
Q34068746	Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
Q36412642	Management of extracranial carotid artery disease
Q41526067	Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease
Q34655133	Management of hypercholesterolaemia in postmenopausal women
Q33616889	Management of hypercholesterolemia. A primary care perspective
Q38704442	Management of hypercholesterolemia. Approach to diet and drug therapy
Q36683581	Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association
Q37907067	Management of hyperlipidemia of kidney disease
Q41517471	Management of lipid disorders in the elderly
Q39643034	Management of lipids in primary and secondary prevention of cardiovascular diseases
Q34509936	Management of low levels of high-density lipoprotein-cholesterol
Q40679542	Management of older adults with hypercholesterolaemia
Q33843614	Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation
Q35585949	Management of selected lipid abnormalities: hypertriglyceridemia, isolated low HDL-cholesterol, lipoprotein(a), and lipid abnormalities in renal diseases and following solid organ transplantation
Q37951756	Management of the patient with a low HDL-cholesterol
Q38106502	Management of the patient with diabetes and coronary artery disease: a contemporary review
Q34112942	Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials
Q37385184	Managing diabetic dyslipidemia: beyond statin therapy
Q37917094	Managing elevated blood lipid concentrations. Who, when and how?
Q40785855	Meaningful interpretation of risk reduction from clinical drug trials.
Q53428750	Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.
Q28256111	Mechanistic considerations for human relevance of cancer hazard of di(2-ethylhexyl) phthalate
Q71985554	Medical management of peripheral arterial disease
Q35299212	Medical treatment of vertebral osteoporosis
Q42050755	Medication compliance and serum lipid changes in the Helsinki Heart Study
Q38290764	Mendelian randomisation applied to drug development in cardiovascular disease: a review.
Q84187504	Mendelian randomisation, triglycerides, and CHD
Q40948177	Metabolic abnormalities in cardiac ischemia.
Q35583599	Metabolic syndrome – a new risk factor of coronary heart disease?
Q37982204	Metabolic syndrome: definition and therapeutic implications
Q37901053	Metabolic syndrome: nature, therapeutic solutions and options
Q57012269	Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs
Q74596886	Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects
Q34228500	MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells
Q41618932	Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia
Q34820339	Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia
Q36497374	Might treatment of hypercholesterolaemia increase non-cardiac mortality?
Q40281693	Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?
Q38158164	Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study.
Q26829098	Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects
Q26770809	Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart
Q37254899	Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes
Q58261877	Mortality Rates after Multifactorial Primary Prevention of Cardiovascular Diseases
Q35847526	Multi-bed vascular disease: past, present, and future
Q36470320	Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease
Q71950424	Multiple biochemical blood testing as a case-finding tool in ambulatory medical patients
Q93563258	Multitherapy for diabetes
Q37563958	Myopathy with statin-fibrate combination therapy: clinical considerations
Q37343344	NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER.
Q43652438	National Cholesterol Education Program: does the emperor have any clothes?
Q24802369	Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
Q28072298	New Era of Lipid-Lowering Drugs
Q36450075	New Insights into the High-Density Lipoprotein Dilemma
Q124634352	New Monoterpenoid Indole Alkaloids from Tabernaemontana crassa Inhibit β-Amyloid42 Production and Phospho-Tau (Thr217)
Q44431620	New MspI polymorphism at +83 bp of the human apolipoprotein AI gene: association with increased circulating high density lipoprotein cholesterol levels
Q90380337	New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Q39603880	New approaches to cholesterol lowering: efficacy and safety
Q34748825	New cholesterol guidelines, new treatment challenges
Q34327251	New developments in atherosclerosis imaging: electron beam tomography
Q34107152	New developments in the treatment of low high-density lipoprotein cholesterol
Q35570944	New drugs for the treatment of hypercholesterolaemia
Q47279052	New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Q26766157	Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens
Q49968075	Niacin for lipid disorders.
Q34300722	Niacin or ezetimibe for patients with, or at risk of coronary heart disease
Q44004071	Niacin: the only vitamin that reduces cardiovascular events
Q34736500	Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.
Q38272551	Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?
Q34107321	Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol
Q69922255	Nonselective beta-receptor blocker effect on high density lipoprotein cholesterol after chronic exercise
Q28084156	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council
Q38397934	Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancers
Q30454244	Number needed to screen: development of a statistic for disease screening.
Q52304087	Number needed to treat is a simple measure of treatment efficacy for clinicians.
Q38451985	Nutraceuticals: Definition and Epidemiological Rationale for Their Use in Clinical Practice.
Q40436417	Nutrition and Coronary Heart Disease Epidemiology
Q71695023	Nutrition and coronary heart disease in the elderly: low fat or laissez-faire?
Q38299618	Nutritional management of plasma lipid disorders
Q34438259	Obesity and disease management: effects of weight loss on comorbid conditions
Q61781878	Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses
Q28076399	Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
Q69791000	Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus
Q36682706	One year experience in the treatment of familial hypercholesterolaemia with simvastatin
Q42551463	Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats
Q28219266	Optimal lipid modification: the rationale for combination therapy
Q36410616	Optimal low-density lipoprotein levels: evidence from epidemiology and clinical trials
Q81097348	Optimal medical therapy with or without percutaneous coronary intervention for stable coronary disease: the COURAGE Study
Q26824004	Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Q44135494	Overall mortality in the program on the surgical control of the hyperlipidemias
Q38704422	Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies
Q36937221	Overviews of pathogen emergence: which pathogens emerge, when and why?
Q46343891	Oxidative effects of gemfibrozil on anion influx and metabolism in normal and Beta-thalassemic erythrocytes: physiological implications.
Q37913064	PET, PTCA, and economic priorities
Q36528512	PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.
Q37996437	PPAR agonists for the treatment of cardiovascular disease in patients with diabetes
Q35080447	PPAR-alpha effects on the heart and other vascular tissues
Q36861044	PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease
Q39200940	PPAR-α agonists are still on the rise: an update on clinical and experimental findings
Q37251719	PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents
Q35631058	PPARalpha agonist-induced rodent tumors: modes of action and human relevance
Q36154953	PPARalpha in atherosclerosis and inflammation
Q37072216	PPARs and the kidney in metabolic syndrome
Q37517687	PPARα activation can help prevent and treat non-small cell lung cancer
Q38038289	PPARα as a therapeutic target in inflammation-associated diseases
Q41911186	PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
Q24540405	Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases
Q33652024	Pathophysiology and management of low high-density lipoprotein cholesterol
Q40743537	Patient compliance and medical research: issues in methodology
Q34224416	Patients' and physicians' perceptions and experience of hypercholesterolaemia: a qualitative study
Q36521207	Patterns of Hypertension and their Implications for Therapy.
Q37413789	Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life
Q92892621	Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
Q70557859	Periodic health examination, 1993 update: 2. Lowering the blood total cholesterol level to prevent coronary heart disease. Canadian Task Force on the Periodic Health Examination
Q36366326	Peroxisome Proliferator-Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia
Q36261125	Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions
Q42988793	Peroxisome proliferator activated receptors and lipoprotein metabolism
Q28289022	Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future
Q37583596	Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?
Q42414964	Peroxisome proliferator-activated receptor alpha target genes.
Q36174039	Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
Q37861955	Peroxisome proliferator-activated receptors and atherosclerosis.
Q34107495	Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms
Q36510464	Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications
Q33307635	Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study
Q50138206	Pharmaceutical care services and results in project ImPACT: hyperlipidemia.
Q33645696	Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
Q37012017	Pharmacogenetics of the PPAR genes and cardiovascular disease
Q35127790	Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy
Q36335716	Pharmacogenomics of cholesterol-lowering therapy
Q33959388	Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
Q41813708	Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis
Q42608089	Pharmacokinetics of pravastatin in elderly versus young men and women
Q42678980	Pharmacokinetics of the combination of fluvastatin and gemfibrozil
Q33665285	Pharmacologic management of triglycerides.
Q37973129	Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes
Q40842144	Pharmacological control of hypertriglyceridemia.
Q92862955	Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
Q39015072	Pharmacological management of diabetic dyslipidemia
Q28218179	Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update
Q38130111	Pharmacotherapies for lipid modification: beyond the statins
Q45772261	Plasma cholesterol, coronary heart disease, and cancer: Authors' reply.
Q38699149	Plasma cholesterol, lipid lowering, and risk for cancer. An update of the results from epidemiologic studies and intervention trials
Q57463626	Plasmapheresis for hypertriglyceridemia: The association between blood viscosity and triglyceride clearance rate
Q36232396	Pleiotropic effects of fibrates
Q68317909	Polymorphisms of the gene encoding cholesterol ester transfer protein and serum lipoprotein levels in subjects with and without coronary heart disease
Q44600063	Poor Lipid Control in Type-2 Diabetics With and Without Ischemic Heart Disease
Q43605177	Poor adherence with hypolipidemic drugs: a lost opportunity
Q38677457	Population strategies of cardiovascular disease prevention: scientific base, rationale and public health implications
Q41808858	Positive relationship between dietary fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs
Q34384114	Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus
Q51572977	Postprandial hemorrheology and apolipoprotein B metabolism in patients with familial hypertriglyceridemia.
Q51605564	Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridaemia: effects of gemfibrozil
Q37786742	Practical drug therapy for common hyperlipidaemias
Q71789074	Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study)
Q58863709	Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolaemia
Q41348490	Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease
Q36691444	Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
Q43778219	Prescribing propensity: influence of life-expectancy gains and drug costs
Q36795404	Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer
Q34003407	Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment
Q37742379	Prevention and regression of atherosclerosis with drug therapy
Q34220548	Prevention of a first myocardial infarction
Q49967737	Prevention of atherosclerosis.
Q77714696	Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
Q33859347	Prevention of coronary heart disease. Part I. Primary prevention
Q42379851	Preventive therapies: weighing the pros and cons.
Q57745957	Primary Prevention Drug Therapy: Can It Meet Patients’ Requirements for Reduced Risk?
Q22241916	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association
Q68839622	Primary care residents and the management of hypercholesterolemia
Q83649345	Primary prevention of CVD: treating dyslipidaemia
Q33446730	Primary prevention of CVD: treating dyslipidaemia.
Q40890532	Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? West Of Scotland Coronary Prevention Study.
Q34025127	Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions
Q71043635	Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension
Q34188855	Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management
Q28211326	Progestogens with antiandrogenic properties
Q71907125	Prognostic role of cardiovascular risk factors for men with cardiomegaly (the Reykjavik Study)
Q44106401	Program on the surgical control of the hyperlipidemias (POSCH): Patient entry characteristics
Q29619982	Progress and challenges in translating the biology of atherosclerosis
Q38839105	Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.
Q44053357	Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels
Q36536280	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
Q37494202	Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review
Q40915448	Psychobehavioral treatment in cardiac rehabilitation.
Q67779028	Psychologic effects of the diagnosis and treatment of hypercholesterolemia: Lessons from case studies
Q50672929	Publication bias in presentations to the Annual Scientific Congress.
Q39383249	Putting medical practice guidelines into practice: the cholesterol model.
Q36847905	QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population.
Q71371355	Quantitation of apolipoprotein E
Q70711834	Quantitative angiographic follow-up studies on the development of coronary artery disease: which coronary segments should be analyzed? Experience from INTACT
Q89336081	Quinoa Seed Lowers Serum Triglycerides in Overweight and Obese Subjects: A Dose-Response Randomized Controlled Clinical Trial
Q44270707	Race and gender differences in serum lipoproteins of children, adolescents, and young adults—Emergence of an adverse lipoprotein pattern in white males: The Bogalusa Heart Study
Q34271942	Raising HDL cholesterol in women.
Q33702194	Randomised controlled trial in northern England of the effect of a person knowing their own serum cholesterol concentration
Q40421165	Range of serum cholesterol values in the population developing coronary artery disease
Q36920620	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy
Q33578422	Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial
Q36025974	Rationale for combination therapy with statin drugs in the treatment of dyslipidemia
Q34107307	Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk
Q33843402	Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention
Q34107158	Recent developments in the treatment of hypertriglyceridemia
Q36410620	Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.
Q79433533	Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol
Q36647492	Reductase inhibitor therapy of hypercholesterolemia
Q68765036	Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study
Q38679335	Reduction in coronary heart disease: clinical and anatomical considerations
Q44177995	Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice
Q52220887	Reflex testing I: algorithm for lipid and lipoprotein measurement in coronary heart disease risk assessment.
Q38160494	Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes
Q34117515	Regression of coronary atherosclerosis: is it possible?
Q37787958	Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products
Q37350108	Regulation of rat hepatic low density lipoprotein receptors. In vivo stimulation by growth hormone is not mediated by insulin-like growth factor I.
Q35212558	Regulation of reverse cholesterol transport and clinical implications
Q40915415	Rehabilitative exercise for the cardiac patient. Early phase.
Q42578253	Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis
Q67870981	Relationship of skeletal muscle fiber type to serum high density lipoprotein cholesterol and apolipoprotein A-I levels
Q38007038	Relative efficacy of antilipemic agents in non–high-density lipoprotein cholesterol reduction
Q71015670	Relative survival benefits of risk factor modifications
Q39417751	Relevance of cholesterol screening in the United Arab Emirates. A preliminary study
Q72616634	Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria
Q33646061	Resource utilisation in the management of dyslipidaemia
Q36271331	Results of microsurgical carotid endarterectomy. A prospective study with transcranial Doppler and EEG monitoring, and elective shunting
Q71774498	Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study
Q70244057	Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy)
Q99402803	Retrospective analysis of the cholesterol levels in a European mid-latitude population between 2007 and 2018: controversies and therapeutic implications
Q36300834	Reverse cholesterol transport and cholesterol efflux in atherosclerosis
Q41171305	Review of the major intervention trials of lowering coronary artery disease risk through cholesterol reduction
Q64237412	Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability
Q37153566	Risk factor management to prevent first stroke
Q41742297	Risk factor modification: rationale for management of dyslipidemia
Q35714390	Risk factors and 25 year risk of coronary heart disease in a male population with a high incidence of the disease: the Finnish cohorts of the seven countries study
Q41612001	Risk factors for cardiovascular disease in children with type I diabetes: Part 1.
Q39578990	Risk factors for coronary heart disease. Selected recent epidemiological advances
Q40665059	Risk-benefit assessment of drug treatment to prevent coronary heart disease. Estimating the benefits of risk factor modification
Q33599854	Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans
Q36104056	Rodent carcinogenicity of peroxisome proliferators and issues on human relevance
Q41731956	Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia
Q38684505	Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
Q38221965	Role of HDL in those with diabetes
Q43585851	Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population
Q37811855	Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Q33652033	Role of fibrates in the management of hypertriglyceridemia
Q35904825	Role of fibric acid derivatives in the management of risk factors for coronary heart disease
Q38933872	Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
Q34258041	Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys
Q37231752	Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.
Q37051264	Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
Q36802569	Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia
Q34509418	Rosuvastatin for the treatment of patients with hypercholesterolemia
Q34196622	Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust
Q34221135	Screening and treating adults for lipid disorders.
Q72005574	Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study
Q67856624	Screening for Coronary Heart Disease Risk in the Elderly: Total Cholesterol Versus High-Density Lipoprotein—Cholesterol
Q31031645	Screening for cardiovascular disease with cholesterol
Q34580019	Screening for hypercholesterolemia among Canadians: how much will it cost?
Q43604249	Screening for hypercholesterolemia in children: The missing links
Q40889824	Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care
Q38041209	Second line options for hyperlipidemia management after cardiac transplantation.
Q77377861	Selective opportunistic screening for hypercholesterolemia in primary care practice
Q38110581	Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists
Q68701043	Selective screening for high cholesterol in Australian general practice: the Newcastle Cholesterol Prediction Study
Q44472473	Sensitive method for the quantitative determination of gemfibrozil in dog plasma by liquid-liquid cartridge extraction and liquid chromatography-tandem mass spectrometry
Q37002719	Separation of the principal HDL subclasses by iodixanol ultracentrifugation
Q59797390	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies
Q51563933	Serum cholesterol and impulsivity in personality disorders.
Q47957510	Serum cholesterol levels are underevaluated and undertreated
Q51088271	Serum cholesterol, suicidal tendencies, impulsivity, aggression, and depression in adolescent psychiatric inpatients.
Q33702528	Serum lipid and apolipoprotein distributions in Hong Kong Chinese
Q77714845	Serum lipid physiology and the influence of glaucoma medications
Q34239262	Serum lipid profile in suicide attempters.
Q33702532	Serum lipids and mood in working men and women in Sweden
Q34562290	Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects.
Q41731977	Serum triglycerides and clinical benefit in lipid-lowering trials
Q43892677	Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
Q43856637	Sexual dysfunction secondary to gemfibrozil
Q44105671	Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia
Q36446970	Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
Q36385133	Should all diabetic patients receive statins?
Q46199534	Should we treat all primary prevention patients with statins?
Q67856221	Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment
Q43459154	Simvastatin and cholestyramine in the long-term treatment of hypercholesterolaemia
Q58421218	Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia
Q72664928	Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria
Q40923088	Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia
Q33560221	Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease
Q46775567	Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.
Q39408868	Small area analysis: abortion statistics
Q24541529	Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis
Q36682305	Specific lipid lowering therapy in the management of diabetes
Q37036416	Standards of medical care in diabetes--2009.
Q33554238	Standards of medical care in diabetes--2010.
Q34425055	Standards of medical care in diabetes--2011.
Q24632533	Standards of medical care in diabetes--2012
Q29620309	Standards of medical care in diabetes--2013
Q77896411	State-of-the-art update and review: clinical trials of lipid-lowering agents
Q24603957	Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism
Q38881156	Statin combination therapy and cardiovascular risk reduction
Q37738353	Statin effects on both low-density lipoproteins and high-density lipoproteins: is there a dual benefit?
Q35086797	Statin therapy in the elderly: does it make good clinical and economic sense?
Q90283434	Statins and Cardiovascular Disease Outcomes in Chronic Kidney Disease: Reaffirmation vs. Repudiation
Q24245521	Statins and fibrates for preventing melanoma
Q28196669	Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: a monitoring test of endothelial dysfunction for clinical practice?
Q71520573	Statins prevent coronary heart disease
Q33876942	Statins: effective antiatherosclerotic therapy
Q36885016	Statistical problems
Q68154426	Statistics and the practicing physician
Q37757988	Strategies for the development of new PPAR agonists in diabetes
Q37924859	Strength training and lipoprotein-lipid profiles. A critical analysis and recommendations for further study
Q34345675	Stress responses after treatment of hypercholesterolaemia with simvastatin
Q37869454	Synergistic Effect of Persistent Chlamydia pneumoniae Infection, Autoimmunity, and Inflammation on Coronary Risk
Q44539058	Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels
Q42750120	Synthesis and anti-hyperlipidemic evaluation of N‑(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats.
Q38904497	Targeting ApoC-III to Reduce Coronary Disease Risk
Q33746670	Targeting HDL-mediated cellular cholesterol efflux for the treatment and prevention of atherosclerosis
Q38431166	Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance
Q38553529	Targeting inflammation in metabolic syndrome.
Q34491335	Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial
Q34336868	Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit
Q42418260	The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for cholesterol management and for cardiovascular risk stratification: a reappraisal
Q77130225	The 4S study and its pharmacoeconomic implications
Q36783686	The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses
Q35871965	The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus
Q73310982	The Air Force/Texas Coronary Atherosclerosis Prevention Study: implications for preventive cardiology in the general adult US population
Q60955111	The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
Q92333057	The Diagnosis and Treatment of Hypertriglyceridemia
Q57475802	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
Q35179555	The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention
Q41190039	The Helsinki Heart Study: central findings and clinical implications
Q58088776	The Lescol ® Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease
Q41186984	The Lipid Research Clinics Coronary Primary Prevention Trial: design, results, and implications
Q64923599	The Microvascular and Macrovascular Benefits of Fibrates in Diabetes and the Metabolic Syndrome: A review.
Q46249387	The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.
Q39185669	The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.
Q37311116	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient
Q89534430	The Rise and Fall "ing" of the HDL Hypothesis
Q36882866	The Treatment of Disorders of Lipid Metabolism
Q43572386	The US National Cholesterol Education Program. Adult treatment guidelines
Q43274592	The Vytorin on Carotid-Media Thickness and Overall Arterial Rigidity (VYCTOR) study
Q41669925	The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
Q77569198	The antiatherogenic role of high-density lipoprotein cholesterol
Q41353980	The case for aggressive lipid regulation
Q34666872	The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women
Q41063495	The cholesterol controversy
Q93506003	The cholesterol controversy
Q68469427	The cholesterol pessimist
Q35657834	The cholesterol-heart disease hypothesis (critique)--time to change course?
Q36943340	The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic
Q38755818	The clinical significance of serum high density lipoproteins
Q41844442	The clofibrate saga: a retrospective commentary
Q43614828	The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens
Q77172536	The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin
Q57346096	The cost of screening for hypercholesterolaemia– results from a clinical trial in Swedish primary health care
Q33646066	The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines
Q37230691	The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice
Q37833584	The economics of cholesterol lowering
Q35191722	The effect of physical exercise on reverse cholesterol transport
Q38306811	The effect of sucralfate on serum lipids and lipoproteins in normal volunteers [corrected]
Q46711975	The effects of Lactobacillus-fermented milk on lipid metabolism in hamsters fed on high-cholesterol diet.
Q44092959	The effects of combination therapy with niceritrol and pravastatin on hyperlipidaemia
Q46010865	The effects of dietary cholesterol-lowering on psychological symptoms: a randomised controlled study.
Q33778872	The effects of information framing on the practices of physicians
Q72714228	The effects of lowering serum cholesterol on coronary heart disease risk
Q33818141	The evolving role of statins in the management of atherosclerosis
Q34042836	The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies
Q39579005	The future of pharmacological therapy for risk factor reduction. Hyperlipidaemia
Q43139042	The hemodynamic basis of atherosclerosis.
Q38634416	The hyperlipoproteinemias
Q43447174	The hypolipidemic activity of heterocyclic amine boranes in rodents
Q42999514	The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate
Q38660994	The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers
Q40898416	The independent roles of diet and serum lipids in the 20th-century rise and decline of coronary heart disease mortality
Q45038067	The influence of gemfibrozil on malondialdehyde level and paraoxonase 1 activity in wistar and fisher rats
Q30585156	The interpretation and clinical application of data from trials on sudden cardiac death
Q73464242	The management of hypercholesterolemia in patients with coronary artery disease: guidelines for primary care
Q33569142	The metabolic syndrome
Q36039083	The metabolic syndrome: diagnosis and treatment
Q24804541	The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
Q38118163	The need for combination drug therapies in patients with complex dyslipidemia
Q32061351	The neuropsychopharmacology of criminality and aggression
Q38267131	The new cholesterol treatment guidelines from the American College of Cardiology/American Heart Association, 2013: what clinicians need to know
Q34113923	The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis
Q28277233	The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part IV: the 1984 coronary primary prevention trial ends it--almost
Q39637861	The pediatrician's role in atherosclerosis prevention
Q41018882	The practical impact of pharmacoeconomics on institutional managers
Q82691053	The prescribing of lipid lowering drugs during a 1-year period: analysis of 7490 health insurance files
Q35794818	The prevalence, awareness and treatment of high low density lipoprotein-cholesterol in korean adults without coronary heart diseases - the third Korea national health and nutrition examination survey, 2005 -.
Q35371261	The prevention of atherosclerosis with antioxidants
Q74072001	The priming effect of gemfibrozil on reactive oxygen metabolism of phagocytic leucocytes. An intriguing side effect
Q33724526	The regulation of acetyl-CoA carboxylase--a potential target for the action of hypolipidemic agents
Q39668034	The relationship among brain natriuretic peptide (BNP), cholesterol and lipoprotein
Q46952308	The role of fenofibrate in clinical practice
Q35692031	The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy
Q34027549	The role of fibric acid derivatives in the secondary prevention of coronary heart disease
Q34730815	The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer
Q35060328	The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Athe
Q50517734	The sense of coherence, occupation and the risk of coronary heart disease in the Helsinki Heart Study.
Q38609001	The status of hypertriglyceridemia as a risk factor for coronary heart disease.
Q36144312	The triad of shift work, occupational noise, and physical workload and risk of coronary heart disease
Q73902389	The undertreatment of LDL-cholesterol: addressing the challenge
Q95492629	The use of fibric Acid derivatives in cardiovascular prevention
Q45915601	The working group replies.
Q34285956	Therapeutic considerations for postprandial dyslipidaemia
Q37239037	Therapeutic effects of fibrates in postprandial lipemia
Q34621797	Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus
Q42181332	Therapeutic priorities of Canadian internists
Q37981725	Therapeutic strategies to deplete macrophages in atherosclerotic plaques
Q35101124	Therapeutic targets in cardiovascular disease: a case for high-density lipoprotein cholesterol
Q36407298	Therapeutic use of the high-density lipoprotein protein and peptides
Q44088623	Thiourea-based gemfibrozil analogues as HDL-elevating agents
Q34522522	Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.
Q37658719	Toxicogenomics and cross-species biomarker discovery: applications in drug discovery and safety assessment
Q40950575	Trans fatty acids: implications for health, analytical methods, incidence in edible fats and intake (a review).
Q42702483	Transient symptomatic hypotension in patients on simvastatin
Q35125390	Treating Dyslipidemic Patients with Lipid‐Modifying and Combination Therapies
Q41021927	Treating elevated cholesterol levels: the great Satan in perspective
Q37581206	Treating hypertension and cardiovascular risk: are there trade-offs?
Q73574896	Treating isolated low high-density lipoprotein cholesterol: prescient or premature?
Q38201721	Treating low high-density lipoprotein cholesterol: what is the evidence?
Q24793111	Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities
Q37620567	Treating serum lipid abnormalities in high-priority patients
Q70929811	Treatment and control of hypercholesterolemia and hypertension in persons with and without diabetes
Q73919585	Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?
Q33887783	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
Q71857088	Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage
Q51623905	Treatment of coronary heart disease by diet and exercise: fasting and diurnal lipoproteins.
Q36682315	Treatment of diabetes: the effect on serum lipids and lipoproteins
Q27026114	Treatment of dyslipidemia
Q34451791	Treatment of dyslipidemia in diabetes
Q36077229	Treatment of dyslipidemia in the elderly
Q51550714	Treatment of familial hypertriglyceridaemia with acarbose.
Q39570697	Treatment of hypercholesterolemia in black patients
Q41901294	Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin
Q36560981	Treatment of hypertriglyceridemia
Q42669466	Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes
Q35918843	Treatment of lipids and type 2 diabetes
Q44105863	Treatment of nephrotic hyperlipoproteinemia with gemfibrozil
Q47987148	Treatment of severe hypertriglyceridemia lowers plasma viscosity
Q44677541	Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults
Q34099851	Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087
Q34657896	Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys
Q92649743	Trials in "True" Dyslipidemic Patients Are Urged to Reconsider Comprehensive Lipid Management as a Means to Reduce Residual Cardiovascular Risk
Q50977169	Triglyceride expression.
Q58550770	Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Q38034775	Triglyceride-rich lipoproteins and atherosclerosis
Q34181381	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Q26745946	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Q33700652	Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?
Q49211637	Triglycerides and endothelial function in type 2 diabetes.
Q40828853	Triglycerides are more important in atherosclerosis than epidemiology has suggested
Q91926577	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes
Q36907193	Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system
Q90631294	Understanding the Complex of Suicide in Depression: from Research to Clinics
Q50957062	Understanding the variability in the effectiveness of community heart health programs: a meta-analysis.
Q40925433	Unstable angina: new insights into pathophysiologic characteristics, prognosis, and management strategies
Q37019924	Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing
Q40476568	Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Q24678615	Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
Q35903762	Use of fibrates in the United States and Canada
Q26765234	Use of fibrates in the metabolic syndrome: A review
Q34065021	Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
Q89312828	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options
Q73887989	Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction
Q37926333	Using lipid-lowering agents effectively. When diet is not enough
Q48922228	Using serum cholesterol to identify high risk and stimulate behavior change: will it work?
Q41109529	Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression
Q46453144	VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate
Q46068078	Validation of the Archimedes Diabetes Model
Q35824568	Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels
Q34107218	Vascular biology, atherosclerosis, and implications for cardiac care
Q83682134	Veratric acid ameliorates hyperlipidemia and oxidative stress in Wistar rats fed an atherogenic diet
Q61163108	Vitamin D and prostate cancer
Q58176476	What Your Future Doctor Should Know About Statistics: Must-Include Topics for Introductory Undergraduate Biostatistics
Q44980562	What are the facts on cholesterol? Questions physicians often ask about screening and treatment
Q72824452	What do angiographic changes after cholesterol lowering mean?
Q94001073	What every doctor wants to know about cholesterol: answers to some difficult questions
Q39528844	What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?
Q39599336	When and how to treat the dyslipidemias
Q36414944	When does a man need a check-up?
Q37307995	When high is low: raising low levels of high-density lipoprotein cholesterol
Q24804259	Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
Q69224262	Who is for cholesterol testing?
Q35825240	Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation
Q33607440	Why are low-density lipoproteins atherogenic?
Q77709236	Why cholesterol as a central theme in coronary artery disease?
Q41156152	Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence
Q37924723	Women and coronary artery disease. Gender confers no immunity
Q72936659	[Comparison of the efficacy between simvastatin and gemfibrozil in primary hypercholesterolemia]
Q74178835	[Control of cholesterolemia in Spain, 2000. A tool for cardiovascular prevention]
Q74219044	[Guidelines of the Spanish Society of Cardiology for cardiovascular disease prevention and cardiac rehabilitation]
Q73705089	[How relevant is statin therapy for clinical practice?]
Q87437305	[Lipid therapy for patients with coronary heart disease and diabetes. Current state and perspectives]
Q88025019	[Part I. Fibrates in primary and secondary prevention]
Q88025020	[Part II. Combination statin plus fibrate regimens (free and fixed)]
Q68015539	[Pathophysiology and therapy of lipid metabolism disorders in kidney diseases]
Q74639187	[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]
Q78236773	[Primary nutritional and drug prevention of atherosclerosis]
Q81254425	[Statins in coronary patients: a solved issue?]
Q50108522	[The prevalence of classic cardiovascular risk factors in a working Mediterranean population of 4996 men]
Q74639211	[Therapy with CSE inhibitors--more than lipid lowering?]
Q79338901	[Validity in a community (with outside verification) of primary prevention studies on hypercholesterolemia]

P356	DOI	10.1056/NEJM198711123172001
P698	PubMed publication ID	3313041

P2093	author name string	Huttunen JK
		Manninen V
		Frick MH
		Heinonen OP
		Elo O
		Koskinen P
		Heinsalmi P
		Haapa K
		Helo P
		Kaitaniemi P
P433	issue	20
P407	language of work or name	English	Q1860
P921	main subject	gemfibrozil	Q384295
		dyslipidemias	Q66291209
		coronary artery disease	Q844935
P304	page(s)	1237-1245
P577	publication date	1987-11-01
P1433	published in	The New England Journal of Medicine	Q582728
P1476	title	Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
P478	volume	317

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

scientific article

Reverse relations